Opinion|Videos|November 16, 2026

Differentiating BTK Inhibitors in CLL Treatment Selection

The panelists discussed how to differentiate Bruton tyrosine kinase (BTK) inhibitors when selecting treatment for chronic lymphocytic leukemia (CLL), beginning with mechanism.

The panelists discussed how to differentiate Bruton tyrosine kinase (BTK) inhibitors when selecting treatment for chronic lymphocytic leukemia (CLL), beginning with mechanism. They explained that ibrutinib, acalabrutinib, and zanubrutinib bind covalently at a cysteine residue in BTK and that resistance is most often driven by mutation at that site, whereas noncovalent pirtobrutinib remains active after covalent BTK inhibitor failure. They reviewed how head-to-head safety data moved US practice away from ibrutinib toward next-generation covalent agents. The panelists described acalabrutinib and zanubrutinib as largely interchangeable in the frontline setting, citing differences in headache and hypertension but no randomized comparison. They positioned frontline pirtobrutinib for selected patients, such as those with baseline cardiovascular comorbidities, and noted that the value of a covalent agent after pirtobrutinib remains uncertain. They also distinguished patients who stopped a covalent agent for intolerance, who can receive another, from those with resistance, who should move to pirtobrutinib.


Related to this article